Glucocorticoids and TGF-beta1 synergize in augmenting fibroblast mediated contraction of collagen gels.
TGF-beta plays a central role in the initiation and progression of pulmonary fibrosis. Glucocorticoids are frequently used to treat fibrotic diseases, but beneficial effects are often modest. Both TGF-beta and glucocorticoids have been reported to increase fibroblast contraction of native collagen gels, a model of fibrotic tissue remodeling. Therefore, we sought to determine how glucocorticoids interact with TGF-beta in this system. In this study, human fetal lung fibroblasts (HFL-1) were pretreated with or without TGF-beta for 72 h before they were cast into type I collagen gels. Various concentrations of glucocorticoids (budesonide or hydrocortisone) were added at the time of casting. Gel size was then monitored at different times after gel release. The surrounding media were collected for the assay of prostaglandin E2 (PGE2) and the cell lysates were analyzed for cyclooxygenase (COX) expression by immunoblot. Glucocorticoids alone significantly enhanced fibroblast-mediated contraction of collagen gels (P < 0.01) and dose-dependently inhibited PGE2 release by HFL-1 fibroblasts. TGF-beta significantly augmented gel contraction but also induced a 30% increase in PGE2 release and increased the expression of COX-1. Glucocorticoids inhibited TGF-beta1 induced-PGE2 release, and enhanced TGF-beta augmented gel contraction without significantly affecting TGF-beta augmented COX-1 expression. Indomethacin, a COX inhibitor, increased TGF-beta augmented gel contraction but had no further effect when added together with glucocorticoids. Thus, glucocorticoids can synergize with TGF-beta in augmenting fibroblast mediated collagen gel contraction through the inhibition of PGE2 production. Such interactions between glucocorticoids and TGF-beta may account, in part, for the lack of response of fibrotic diseases to glucocorticoids.
Wen
F Q
FQ
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-5125, USA.
Sköld
C M
CM
Liu
X D
XD
Ertl
R F
RF
Zhu
Y K
YK
Kohyama
T
T
Wang
H
H
Rennard
S I
SI
D019819:Budesonide / Q000494:pharmacology; D002460:Cell Line; D003094:Collagen / Q000378:metabolism; D051545:Cyclooxygenase 1; D015232:Dinoprostone / Q000096:biosynthesis; D004357:Drug Synergism; D005347:Fibroblasts / Q000187:drug effects* / Q000502:physiology*; D005355:Fibrosis; D005782:Gels; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007527:Isoenzymes / Q000378:metabolism; D008565:Membrane Proteins; D008954:Models, Biological; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*
D005782:Gels; D005938:Glucocorticoids; D007527:Isoenzymes; D008565:Membrane Proteins; D016212:Transforming Growth Factor beta; D019819:Budesonide; D003094:Collagen; D051545:Cyclooxygenase 1; C496511:PTGS1 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; D006854:Hydrocortisone